Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 4;31(4):671-704.
doi: 10.1080/13218719.2023.2206870. eCollection 2024.

Methamphetamine dependence in Australia-why is 'ice' (crystal meth) so addictive?

Russ Scott  1
Affiliations

Methamphetamine dependence in Australia-why is 'ice' (crystal meth) so addictive?

Russ Scott. Psychiatr Psychol Law. .

Abstract

Australia has one of the highest rates in the world of the use of the crystalline form of methamphetamine, a highly addictive stimulant that is often associated with a chronic, relapsing dependency. Methamphetamine use is associated with both acquisitive and violent offending, which cause substantial personal and societal costs. Whilst the short-term euphoria and stimulation provide a positive reinforcement to methamphetamine use, the aversive states of withdrawing from methamphetamine and the associated craving, which may last up to five weeks into abstinence, underlie the negative reinforcement to continued methamphetamine use. Although many methamphetamine-dependent users experience high levels of psychological distress, it is likely that less than half engage with treatment or support services, and current intervention and treatment programmes have high discontinuation rates. Stigma and discrimination, even from paramedics and health clinicians, are prominent barriers to methamphetamine-dependent users accessing treatment in Australia.

Keywords: addiction; craving; dependence; discrimination; methamphetamine; stigma.

PubMed Disclaimer

Conflict of interest statement

Russ Scott has declared no conflicts of interest

References

    1. Acheson, L. S., Ezard, N., Lintzeris, N., Dunlop, A., Brett, J., Rodgers, C., Gill, A., Christmass, M., McKetin, R., Farrell, M., Shoptaw, S., & Siefried, K. J. (2022). Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial. Drug and Alcohol Dependence, 241, 109692. 10.1016/j.drugalcdep.2022.109692 - DOI - PubMed
    1. Acheson, L. S., Williams, B. H., Farrell, M., McKetin, R., Ezard, N., & Siefried, K. J. (2023). Pharmacological treatment for methamphetamine withdrawal: A systematic review and meta‐analysis of randomised controlled trials. Drug and Alcohol Review, 42(1), 7–19. 10.1111/dar.13511 - DOI - PMC - PubMed
    1. Adams, V. J. M., & Volkow, N. D. (2020). Ethical imperatives to overcome stigma against people with substance use disorders. AMA Journal of Ethics, 22(8), 702–708. - PubMed
    1. Addison, M., Kaner, E., Spencer, L., McGovern, W., McGovern, R., Gilvarry, E., & O'Donnell, A. (2021). Exploring pathways into and out of amphetamine type stimulant use at critical turning points: a qualitative interview study. Health Sociology Review: The Journal of the Health Section of the Australian Sociological Association, 30(2), 111–126. 10.1080/14461242.2020.1811747 - DOI - PubMed
    1. Akindipe, T., Wilson, D., & Stein, D. J. (2014). Psychiatric disorders in individuals with methamphetamine dependence: prevalence and risk factors. Metabolic Brain Disease, 29(2), 351–357. 10.1007/s11011-014-9496-5 - DOI - PubMed